Roche’s Evrysdi ramps up SMA rivalry with Novartis and Biogen thanks to FDA nod in newborns

Roche’s Evrysdi ramps up SMA rivalry with Novartis and Biogen thanks to FDA nod in newborns
kdunleavy
Tue, 05/31/2022 – 10:31
Click here to view original post